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Abstract
Aims/hypothesis Activation of the receptor for AGE (RAGE) has been shown to be associated with diabetic nephropathy. The
soluble isoform of RAGE (sRAGE) is considered to function as a decoy receptor for RAGE ligands and thereby protects against
diabetic complications. A possible association between sRAGE and diabetic nephropathy is still, however, controversial and a
more comprehensive analysis of sRAGE with respect to diabetic nephropathy in type 1 diabetes is therefore warranted.
Methods sRAGE was measured in baseline serum samples from 3647 participants with type 1 diabetes from the nationwide
multicentre Finnish Diabetic Nephropathy (FinnDiane) Study. Associations between sRAGE and diabetic nephropathy, as well
as sRAGE and diabetic nephropathy progression, were evaluated by regression, competing risks and receiver operating charac-
teristic curve analyses. The non-synonymous SNP rs2070600 (G82S) was used to test causality in the Mendelian randomisation
analysis.
Results Baseline sRAGE concentrations were highest in participants with diabetic nephropathy, compared with participants with
a normal AER or those with microalbuminuria. Baseline sRAGE was associated with progression from macroalbuminuria to
end-stage renal disease (ESRD) in the competing risks analyses, but this association disappeared when eGFRwas entered into the
model. The SNP rs2070600 was strongly associated with sRAGE concentrations and with progression frommacroalbuminuria to
ESRD. However, Mendelian randomisation analysis did not support a causal role for sRAGE in progression to ESRD.
Conclusions/interpretation sRAGE is associated with progression frommacroalbuminuria to ESRD, but does not add predictive
value on top of conventional risk factors. Although sRAGE is a biomarker of diabetic nephropathy, in light of the Mendelian
randomisation analysis it does not seem to be causally related to progression from macroalbuminuria to ESRD.
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Abbreviations
ESRD End-stage renal disease
RAGE Receptor for AGE
ROC Receiver operating characteristic
sRAGE Soluble receptor for AGE
Introduction
Diabetic nephropathy is associated with increased premature
mortality in those with type 1 diabetes [1], but the genetic and
biochemical factors involved in the pathogenesis of diabetic
nephropathy are not fully understood. The receptor for AGE
(RAGE) has been implicated in the development of diabetic
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nephropathy. RAGE binds several ligands, of which the AGEs
are of importance for diabetic complications due to their ac-
celerated formation in the diabetic milieu [2]. The AGE–
RAGE interaction initiates deleterious intracellular signalling
cascades causing activation of the NF-κB pathway. The solu-
ble isoform of RAGE (sRAGE), which originates from the
proteolytic shedding of RAGE by matrix metalloproteinases
and to a lesser extent from alternative mRNA splicing [3],
works as a decoy receptor by preventing AGEs from binding
to the membrane-bound RAGE and thus also prevents RAGE
activation. It is therefore hypothesised that sRAGE is a pro-
tective factor against the development of diabetic complica-
tions. Elevated sRAGE concentrations have been reported in
various kidney diseases [4–9] and even in type 1 diabetes [10].
However, no studies on the role of sRAGE in individuals with
type 1 diabetes with respect to the presence and progression of
diabetic nephropathy have been reported. Therefore, we per-
formed comprehensive analyses on sRAGE in participants
with type 1 diabetes with and without diabetic nephropathy.
Methods
Participants A total of 3647 Finnish participants with type
1 diabetes from the nationwide multicentre Finnish
Diabetic Nephropathy (FinnDiane) Study were included.
Type 1 diabetes was defined as age at onset of 35 years or
younger and initiation of insulin treatment within 1 year
of diagnosis. Blood and urine samples were collected at
baseline and at follow-up (n = 3107) for determination of
HbA1c, AER, serum creatinine and serum sRAGE concen-
trations (by ELISA; Quantikine, R&D Biosystems,
Minneapolis, MN, USA). Other variables, such as clinical
events, medication and lifestyle factors, were obtained
from a thorough clinical examination and completion of
standardised questionnaires by the attending physician.
Diabetic nephropathy was defined as AER ≥200 μg/min
or ≥300 mg/24 h in two out of three consecutive over-
night or 24 h urine collections, and end-stage renal dis-
ease (ESRD) as dialysis or kidney transplantation. Normal
AER was defined as <20 μg/min or <30 mg/24 h and
microalbuminuria as 20–199 μg/min or 30–299 mg/24 h.
eGFR was estimated using the Chronic Kidney Disease
Epidemiology Collaboration formula [11]. SNP genotyp-
ing was performed using the Homogenous Mass Extend
MassArray System (Sequenom, San Diego, CA, USA)
and the ABI Prism 7900 Sequence Detector System
(Applied Biosystems, Foster City, CA, USA) according
to the manufacturers’ instructions. The study was ap-
proved by the local ethics committees and the study was
performed according to the Declaration of Helsinki. All
participants provided written informed consent.
Statistical analyses For the baseline analyses regarding diabet-
ic nephropathy (yes/no), participants with normal AER and
microalbuminuria were compared with participants with
macroalbuminuria and ESRD, excluding those with a renal
transplant. Log-transformation was used to obtain normal
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distribution for triacylglycerols and AER. Pearson’s and
Spearman’s correlations were applied for univariate correla-
tions. Backward linear regression models were used to evalu-
ate associations between clinical variables and sRAGE con-
centration, with a p value of 0.05 for inclusion of a variable in
the model and 0.10 for its removal. Values are given as means
± SD or medians (interquartile range). Analyses were per-
formed using IBM SPSS Statistics 21.0 (IBM Corporation,
Somers, NY, USA).
For the analyses related to the progression of kidney dis-
ease, Kaplan–Meier and multivariable Cox regression analy-
ses were used, with the logrank p value as the measure of
significant difference. The Cox model was adjusted for con-
ventional factors that influence the risk of progression of dia-
betic nephropathy: sex, duration of diabetes, HbA1c, BMI,
systolic BP, triacylglycerols, AER and eGFR. The competing
risks analysis [12] with death as a competing event with pro-
gression to ESRD applied a cumulative incidence function
and was adjusted for the same variables as the Cox regression.
To compare the Cox models with and without sRAGE, receiv-
er operating characteristic (ROC) curve analysis was per-
formed using MedCalc (MedCalc Software, Ostend,
Belgium). At the final stage of the assessments of the relation-
ship between sRAGE and ESRD, a Mendelian randomisation
analysis was performed with ‘ivregress’ with two-stage least-
squares estimator in Stata 11.2 and Stata 15 (Stata Corp LLC,
College Station, TX, USA). The Mendelian randomisation
approach is comparable with RCTs. In an observational study
setting, the genetic markers, which are randomly assigned at
meiosis, can be considered the intervention affecting the out-
come throughout the lifetime of an individual. ESRD, both
prevalent and incident, was used as the endpoint in our anal-
yses and the SNP rs2070600 (G82S) was selected the instru-
mental variable, as we have previously shown that it strongly
influences sRAGE concentrations [13]. A positive association
in the Mendelian randomisation analysis would indicate a
causal role of sRAGE in the development of ESRD. The
SNP’s influence on sRAGE concentrations was estimated
using R (R Foundation for Statistical Computing, Vienna,
Austria). Power for the Mendelian randomisation was calcu-
lated online using mRnd (http://cnsgenomics.com/shiny/
mRnd, accessed 19 March 2019) for the binary outcomes.
Results
Participant characteristics Of the total 3647 FinnDiane partic-
ipants, 2390 (65.5%) had a normal AER, 489 (13.4%) had
microalbuminuria, 513 (14.1%) had macroalbuminuria and
255 (7.0%) had ESRD. The clinical characteristics of all par-
ticipants are summarised in Table 1.
The mean ± SD sRAGE concentration in the entire cohort
was 1265 ± 656 pg/ml (median 1148 pg/ml, interquartile
range 872–1495 pg/ml), with values ranging from 157 to
9621 pg/ml. sRAGE concentrations did not differ between
men (1270 ± 676 pg/ml) and women (1259 ± 634 pg/ml).
sRAGE concentrations correlated asymptotically with eGFR,
meaning that sRAGE concentrations were the highest in indi-
viduals with the poorest native kidney function, as we have
previously reported [13]. Other clinical variables that correlat-
ed with sRAGE concentrations in the univariate analyses in
the entire population and separately for kidney-status groups
are summarised in Electronic Supplementary Material (ESM)
Table 1.
sRAGE concentrations are associated with albuminuria at
baseline The lowest sRAGE concentrations were seen in par-
t ic ipants wi th a normal AER and in those with
microalbuminuria, whereas the highest sRAGE concentra-
tions were observed in participants with macroalbuminuria
and ESRD (Table 1). In logistic regression analysis, sRAGE
was significantly associated with diabetic nephropathy after
correction for confounding factors (sRAGE per 100 pg/ml:
OR 1.066, 95% CI 1.020, 1.114; p = 0.004). However, the
difference in the AUC of the model with (AUC 0.9839) and
without sRAGE (AUC 0.9840) was not significant.
In participants with macroalbuminuria, sRAGE was asso-
ciated with eGFR in linear regression analysis (β −0.356, t
−8.618, p = 8.6× 10−17). In this group, the lowest sRAGE con-
centrations (1093 pg/ml) were seen in the highest eGFR quar-
tile (>117ml min−1 [1.73 m]−2) and the highest concentrations
(1718 pg/ml) in the lowest eGFR quartile (<80.5 ml min−1
[1.73 m]−2) (p = 2.0× 10−6).
Baseline sRAGE concentrations predict progression of diabet-
ic nephropathy in type 1 diabetes but not independently of
eGFR A total of 348 of the 3107 participants with
follow-up data available had progressed from a lower
to the next stage of kidney disease. The mean ± SD
follow-up time was 6.25 ± 2.88 years (range 0–
13.6 years).
During follow-up, 147 of 2063 participants developed
microalbuminuria but sRAGE was not associated with this
change. sRAGE was also not related to progression from
micro- to macroalbuminuria (76 progressors among 418 par-
ticipants). In contrast, every 100 pg/ml increase in sRAGE
was associated with a greater risk of progression from
macroalbuminuria to ESRD (125 progressors out of 457 par-
ticipants; HR 1.051, 95% CI 1.040, 1.062, logrank p = 3.4 ×
10−20) in univariate analysis. In multivariable analyses,
sRAGE remained a significant predictor of progression to
ESRD when sex, duration of type 1 diabetes, HbA1c, log tri-
acylglycerols, BMI, systolic BP, history of smoking and log
AER were entered into the model (HR 1.027, 95% CI 1.011,
1.043; logrank p = 0.001). However, the association disap-
peared after the addition of eGFR into the model.
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Competing risks analyses were performed for progression
from macroalbuminuria to ESRD with death as the competing
event. The competing risk model was adjusted by the same var-
iables as the Cox regression model. sRAGE showed a clear
association with progression to ESRD both as a continuous var-
iable (subdistribution HR 1.000246, 95% CI 1.000022, 1.0047;
logrank p= 0.032) and as quartiles (subdistribution HR 1.567,
95% CI 1.215, 2.023; logrank p = 0.001). However, after enter-
ing eGFR into the model, sRAGE and the sRAGE quartile
(logrank p= 0.058) were no longer significant.
To estimate the value of sRAGE as a predictor of progres-
sion, we performed ROC curve analyses on the Cox multivar-
iable model with and without sRAGE. In the ROC curve
analysis, the AUC including sRAGE was 0.856 (95% CI
0.816, 0.890) and the AUC without sRAGE was 0.908
(95% CI 0.874, 0.935), with a significant difference in the
AUCs (p = 0.027).
SNP and Mendelian randomisation analysis We have previ-
ously reported that sRAGE concentrations are associated with
SNPs in the AGER gene, with rs2070600 (G82S) having the
strongest effect on concentrations [13]. sRAGE concentra-
tions in the different kidney-status groups for the rs2070600
genotype are listed in Table 2. Significant associations were
found between sRAGE and this SNP in all kidney-status
groups except for participants with ESRD (p = 1.2 × 10−37
for participants with a normal AER and p = 4.2 × 10−24 for
all participants).
The SNP rs2070600 was associated with progression from
macroalbuminuria to ESRD in the univariate model (HR 1.13,
95% CI 1.07, 1.19; logrank p = 1.2 × 10−5) as well as in a
multivariable model adjusted for sex, duration of diabetes,
HbA1c, log triacylglycerols, BMI, SBP and history of
smoking (HR 1.08, 95% CI 1.02, 1.14; logrank p = 0.01).
However, after entering log AER and eGFR into the model,
Table 2 SNP rs2070600 genotypes and sRAGE concentrations (pg/ml) in the various kidney-status groups
Genotype Normal
AER
n (%) Micro-
albuminuria
n (%) Macro-
albuminuria
n (%) ESRD n (%) All
participants
n (%)
GG 1247 ± 422 1240 (77.9) 1248 ± 483 282 (74.6) 1712 ± 949 341 (77.9) 1709 ± 1428 144 (80.0) 1359 ± 693 2007 (77.6)
GA 960 ± 331 332 (20.9) 908 ± 355 94 (24.9) 1265 ± 638 94 (21.5) 1993 ± 1866 33 (18.3) 1065 ± 653 553 (21.4)
AA 562 ± 297 20 (1.3) 498 ± 249 2 (0.5) 586 ± 402 3 (0.7) 914 ± 371 3 (1.7) 598 ± 315 28 (1.1)
p value 1.2 × 10−37 1.0 × 10−9 1.7 × 10−5 NS 4.2 × 10−24
Data are means ± SD unless otherwise indicated
The p values indicate the influence of the SNP genotype on the sRAGE concentrations within the groups, calculated by one-way ANOVA
NS, not significant
Table 1 Participant characteris-
tics at baseline Normal AER Microalbuminuria Macroalbuminuria ESRD
n 2390 489 513 255
sRAGE, pg/ml 1177 ± 439 1149 ± 472 1588 ± 893 1660 ± 1366
Men, % 48.0 57.9 58.1 59.4
Age, years 35.3 ± 11.9 38.4 ± 12.0 41.1 ± 10.0 45.9 ± 8.2
Type 1 diabetes duration, years 18.6 ± 12.0 25.7 ± 11.1 28.9 ± 8.1 33.6 ± 7.8
AER, mg/24 h 7 (5–12) 56 (26–109) 500 (178–1311) NA
Serum creatinine, μmol/l 72 (64–81) 77 (68–89) 115 (84–175) 133 (95–363)
eGFR, ml min−1 (1.73 m)−2 107 (93–122) 101 (82–117) 60 (36–89) NA
HbA1c, % 8.1 ± 1.9 8.8 ± 1.6 8.9 ± 1.9 8.1 ± 2.2
HbA1c, mmol/mol 65.2 ± 18.2 72.6 ± 17.2 74.2 ± 19.8 66.3 ± 21.2
BMI, kg/m2 24.8 ± 3.4 25.5 ± 3.6 25.9 ± 4.1 24.0 ± 3.7
Systolic BP, mmHg 129 ± 15 136 ± 17 144 ± 20 152 ± 24
Triacylglycerol, mmol/l 0.9 (0.7–1.3) 1.1 (0.8–1.6) 1.4 (1.0–2.0) 1.4 (1.0–1.9)
HDL-cholesterol, mmol/l 1.4 ± 0.4 1.4 ± 0.4 1.2 ± 0.4 1.2 ± 0.4
LDL-cholesterol, mmol/l 2.9 ± 0.8 3.1 ± 0.8 3.4 ± 0.9 3.1 ± 1.0
Data are means ± SD or median (interquartile range), unless otherwise stated
NA, not applicable
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the association between rs2070600 and progression from
microalbuminuria to ESRD was no longer significant.
In order to evaluate whether sRAGE plays a causative role
in progression from macroalbuminuria to ESRD, we per-
formed a Mendelian randomisation analysis. This methodol-
ogy mimics an RCT in such a way that the alleles assigned
randomly at meiosis are unbiased by other confounding fac-
tors influencing the outcome; in this case, progression to
ESRD. The SNP rs2070600 was used as the instrumental
variable, and explains about 4.2% of the sRAGE variation in
our population. sRAGE was used as the endogenous variable
and ESRD as the main outcome. This analysis provided no
evidence for a causative role of sRAGE in the development of
ESRD (OR −1.89 × 10−5, 95% CI −1.10 × 10−4, 7.24 × 105;
p = 0.685) with an estimated power of 92%.
Discussion
This study explored the potential role of sRAGE in the devel-
opment of diabetic nephropathy and particularly a causal role
in progression from macroalbuminuria to ESRD. Our data
showed that sRAGE is associated with diabetic nephropathy
at baseline, and that baseline sRAGE is also associated with
progression from macroalbuminuria to ESRD. However, fur-
ther analyses showed that sRAGE does not add any predictive
value on top of other conventional risk factors for diabetic
nephropathy and that sRAGE is not causally related to pro-
gression from macroalbuminuria to ESRD.
High sRAGE concentrations have previously been ob-
served in individuals with poor kidney function, albeit with
different underlying causes [4], and those with different types
of diabetes [5], type 1 diabetes [10] and type 2 diabetes [6, 7],
and also in individuals without diabetes [8, 9]. It is noteworthy
that our results are in line with these previous findings, as
sRAGE concentrations were the highest in participants with
diabetic nephropathy at baseline.
There is a strong inverse correlation between sRAGE
and eGFR in individuals with type 1 [10, 13] and type
2 diabetes [14], and even in individuals with non-
diabetic chronic kidney disease [9, 15]. The strong in-
verse correlation between sRAGE and eGFR in partici-
pants with macroalbuminuria observed in the present
study might explain why sRAGE was no longer signif-
icantly associated with progression to ESRD in the Cox
or competing risk regression analyses. Notably, also in
the macroalbuminuric group, sRAGE concentrations
were low when eGFR was normal and high when
eGFR was low, suggesting that eGFR strongly influ-
ences sRAGE concentrations. Whether it is the amount
of sRAGE filtered into the urine that is affected by the
decline in eGFR or that the formation of sRAGE is
increased because of reduced kidney function is not
known. However, it has been suggested that kidney fail-
ure directly influences circulating sRAGE concentrations
[15].
To evaluate the potential role of sRAGE as an additional
risk factor for progression from macroalbuminuria to ESRD,
we performed a ROC curve analysis. In the ROC curve anal-
ysis, sRAGE did not improve the AUC when entered into the
model. This suggests that sRAGE does not, at least in our
population, add new predictive value on top of conventional
risk factors for the development of ESRD.
We furthermore performed a Mendelian randomisation
analysis in a well-powered population to evaluate whether
sRAGE is causally involved in the process leading to ESRD.
This analysis indicated that sRAGE is not causally related to
ESRD, at least in our participants with type 1 diabetes. The
Mendelian randomisation method is not uncomplicated and
pleiotropy, for example, might influence and bias the out-
come, especially if causality is observed. In our case, the
Mendelian randomisation results did not support a causal re-
lationship between sRAGE and ESRD, and the risk of our
results being biased using this method is small. Taken togeth-
er, both the conventional and other statistical methods suggest
that although sRAGE is associated with worsening kidney
function, it is not causally involved in the disease process.
Notably, the present study was observational and not a
mechanistic study, and therefore we can only speculate
about the underlying mechanisms that increase sRAGE
concentration in the presence of kidney disease. As already
pointed out, sRAGE does not seem to be causally involved
in disease progression in light of our results, but it is nev-
ertheless possible that the cell-membrane-bound RAGE
plays an important role in the pathogenesis of diabetic ne-
phropathy through its ability to activate intracellular path-
ways. RAGE activation through ligand binding initiates
deleterious intracellular pathways leading, for example, to
increased expression of cyto- and chemokines and other
inflammatory genes, causing a chronic inflammatory state
[16, 17]. If the association we observed between the SNP
rs2070600 (G82S) and progression to ESRD is a true pos-
itive finding then this might reflect the different degrees of
RAGE activation caused by the different SNP alleles [18,
19] and a more pronounced inflammatory environment
perhaps predisposing to ESRD development. The 82 serine
residue of the SNP rs2070600 is known to enhance binding
of the S100A12 ligand and AGEs. This results in increased
NF-κB expression [19, 20] and also enhanced N-linked
glycosylation at Asn81, which influences the ligand-
binding abilities of RAGE [21]. These differences might
translate into changes in the function of RAGE, but not
necessarily into the function of sRAGE. Therefore, sugges-
tions that sRAGE is a marker of RAGE activation, rather
than being involved in the disease processes [13, 22],
might hold true.
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As high sRAGE concentrations are generally considered
beneficial in other conditions [23, 24], it is unclear why the
high sRAGE concentrations associated with the decline in
renal function are not advantageous and why sRAGE seems
to behave more like a risk factor rather than the protective
factor it is considered to be. Notably, sRAGE does not, to
current knowledge, convey deleterious effects when ligands
are bound and thereby prevents ligands from interacting with
RAGE [17, 25]. In non-diabetic chronic kidney disease, high
sRAGE is associated with smaller intima–media thickness
[26], and a low concentration of endogenous sRAGE is neg-
atively correlated with the aortic calcification index [27]. In
individuals with and without diabetes undergoing peritoneal
dialysis, a low sRAGE concentration has been associated with
accelerated atherosclerosis [28], and in individuals with and
without diabetes undergoing haemodialysis, the vascular cal-
cification index has been reported to be lower in those with
higher sRAGE concentrations [29]. Taken together, these
findings suggest that sRAGE may in some circumstances be
considered beneficial in kidney disease. Such a view is further
supported by animal studies in which administration of
sRAGE was associated with a reduced level or amelioration
of atherosclerotic plaques [30, 31]. It could even be speculated
that sRAGE is not a marker of chronic kidney disease, but
rather of atherosclerosis or chronic inflammation. However,
this requires further study. In type 1 diabetes, we and others
have shown that sRAGE is associated with cardiovascular
mortality independently of kidney disease [10, 13]. It could
also be that sRAGE in our participants with macroalbuminuria
is, through unknown mechanisms, biologically inactive and
accumulates in the circulation because of a decrease in the
eGFR and therefore loses its beneficial effects. Another pos-
sibility is that sRAGE concentrations in renal disease are not
high enough to perform an efficient scavenger function [25,
32] and this phenomenon might be even more prominent in
diabetes, in which large amounts of RAGE ligands such as
AGEs are present. This notion might lead to our results being
interpreted as indicating that sRAGE is not beneficial in renal
disease, as high concentrations are related to worse outcomes.
It has recently been proposed that sRAGE alone may not be a
sufficiently good marker and that the AGE:sRAGE ratio may
be more informative in diseases such as diabetes and renal
disease in predicting the disease process [32, 33]. In future
studies, the ratio between AGEs and sRAGE could be more
thoroughly explored in participants with type 1 diabetes and
kidney disease in order to clarify the discrepancy between a
high sRAGE concentration and disease outcome. Thus, it is
also possible that interventions that leads to a further elevation
of sRAGE concentrations could have therapeutic effects in
individuals with diabetes and those with kidney disease.
To summarise, we have shown that sRAGE is associated
with diabetic nephropathy and its progression in individuals
with type 1 diabetes, but also that sRAGE is a mere marker of
diabetic nephropathy and not necessarily related to the disease
process itself. However, these data do not exclude the possi-
bility that membrane-bound RAGE is involved in the patho-
genesis of diabetic nephropathy.
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